Comparing Adherence to Two Different HIV Antiretroviral Regimens: An Instrumental Variable Analysis
暂无分享,去创建一个
Jonathan R. Nebeker | Joanne LaFleur | Candace Hayden | J. Nebeker | R. Nelson | J. LaFleur | Richard E. Nelson | Larry Reimer | Karen Kone | C. Hayden | L. Reimer | Karen Kone | Larry G. Reimer
[1] F. Maggiolo,et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] J. Miro,et al. A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients. , 2007, Revista clinica espanola.
[3] Richard D Moore,et al. A ten-year analysis of the incidence and risk factors for acute pancreatitis requiring hospitalization in an urban HIV clinical cohort. , 2008, AIDS patient care and STDs.
[4] Sebastian Schneeweiss,et al. Preference-Based Instrumental Variable Methods for the Estimation of Treatment Effects: Assessing Validity and Interpreting Results , 2007, The international journal of biostatistics.
[5] J. Aikens,et al. Patient-reported perceptions of side effects of antihyperglycemic medication and adherence to medication regimens in persons with diabetes mellitus. , 2007, Clinical therapeutics.
[6] B. Walker,et al. Tolerability and Efficacy of PI Versus NNRTI-Based Regimens in Subjects Receiving HAART During Acute or Early HIV Infection , 2009, Journal of acquired immune deficiency syndromes.
[7] A. Monforte,et al. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. , 2005, International journal of antimicrobial agents.
[8] M Alan Brookhart,et al. Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance. , 2009, Journal of clinical epidemiology.
[9] M Alan Brookhart,et al. American Journal of Epidemiology Practice of Epidemiology Instrumental Variable Analysis for Estimation of Treatment Effects with Dichotomous Outcomes , 2022 .
[10] V. Vullo,et al. Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens. , 2001, AIDS.
[11] J. J. Henning,et al. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.
[12] M Alan Brookhart,et al. Evaluating Short-Term Drug Effects Using a Physician-Specific Prescribing Preference as an Instrumental Variable , 2006, Epidemiology.
[13] C. Hicks,et al. Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options. , 2010, The Journal of antimicrobial chemotherapy.
[14] C. Cooper,et al. Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study , 2011 .
[15] T. Mark,et al. Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs. , 2011, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[16] Spyridon S Marinopoulos,et al. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. , 2008, Journal of clinical epidemiology.
[17] M Alan Brookhart,et al. Instrumental Variable Analysis of Secondary Pharmacoepidemiologic Data , 2006, Epidemiology.
[18] Sebastian Schneeweiss,et al. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. , 2005, Journal of clinical epidemiology.
[19] C. Larsen,et al. Inpatient admissions and outpatient visits in persons with and without HIV infection in Denmark, 1995–2007 , 2010, AIDS.
[20] Jonathan H. Wright,et al. A Survey of Weak Instruments and Weak Identification in Generalized Method of Moments , 2002 .
[21] M. González Sagrado,et al. Assessment of factors influencing health‐related quality of life in HIV‐infected patients , 2011, HIV medicine.
[22] M Alan Brookhart,et al. Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. , 2009, Journal of clinical epidemiology.
[23] J. Rassen,et al. Evaluating the Validity of an Instrumental Variable Study of Neuroleptics: Can Between-Physician Differences in Prescribing Patterns Be Used to Estimate Treatment Effects? , 2007, Medical care.
[24] M. Kozal,et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies , 2007, AIDS.
[25] G. Borsboom,et al. The role of 'confounding by indication' in assessing the effect of quality of care on disease outcomes in general practice: results of a case-control study , 2005, BMC health services research.
[26] K. Tashima,et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. , 1999, The New England journal of medicine.
[27] F. Noya,et al. Clinical effectiveness of inhaled corticosteroids versus montelukast in children with asthma: prescription patterns and patient adherence as key factors , 2012, Current medical research and opinion.
[28] M. Beauchesne,et al. Inhaled corticosteroids vs. leukotriene-receptor antagonists and asthma exacerbations in children. , 2011, Respiratory medicine.
[29] M J Gill,et al. Cost of medical care for HIV‐infected patients within a regional population from 1997 to 2006 , 2008, HIV medicine.
[30] D. G. Saple,et al. Physician estimate of antiretroviral adherence in India: poor correlation with patient self-report and viral load. , 2010, AIDS patient care and STDs.
[31] F. Maggiolo,et al. Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring Mutations in NNRTI- or PI-Treated Patients , 2007, HIV clinical trials.
[32] J. Avorn,et al. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? , 2003, The American journal of medicine.
[33] S. Staszewski. Update on study 006--EFV + AZT + 3TC versus the current 'standard of care' IDV + AZT + 3TC. , 1999, International journal of clinical practice. Supplement.
[34] J. Angrist,et al. Identification and Estimation of Local Average Treatment Effects , 1995 .
[35] C. McAdam-Marx,et al. Comparing Medication Adherence Methods in Lipid-Modifying Therapy , 2012 .
[36] M. Moroni,et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients , 2000, AIDS.
[37] Richard D Moore,et al. Inpatient Health Services Utilization Among HIV-Infected Adult Patients in Care 2002–2007 , 2010, Journal of acquired immune deficiency syndromes.
[38] M. Chesney,et al. Patient- and provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence. , 2001, Journal of clinical epidemiology.
[39] K. Ruxrungtham,et al. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV‐infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors , 2007, HIV medicine.
[40] F. Brun-Vézinet,et al. Adherence to Antiretroviral Therapy and Outcomes in HIV-Infected Patients Enrolled in An Induction/Maintenance Randomized Trial , 2001, Antiviral therapy.
[41] C. Savini,et al. Survey of patient and clinician attitudes on adherence in a rural HIV clinic. , 2003, The Journal of the Association of Nurses in AIDS Care : JANAC.
[42] K. Mazor,et al. Predictors of very low adherence with medications for osteoporosis: towards development of a clinical prediction rule , 2010, Osteoporosis International.
[43] O. Kirk,et al. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study , 2004, HIV medicine.
[44] V. Johnson,et al. Consequences and Determinants of Adherence to Antiretroviral Medication: Results from Adult Aids Clinical Trials Group Protocol 370 , 2001, Antiviral therapy.
[45] Yingying Ma,et al. How well do clinicians estimate patients’ adherence to combination antiretroviral therapy? , 2007, Journal of General Internal Medicine.
[46] J. Miro,et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. , 2008, AIDS Research and Human Retroviruses.
[47] J. Cramer,et al. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[48] Steven M. Shechter,et al. Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation. , 2006, The Journal of antimicrobial chemotherapy.
[49] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[50] R. Hamatake,et al. Clinical Utility of Current NNRTIs and Perspectives of New Agents in This Class under Development , 2004, Antiviral chemistry & chemotherapy.